Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study

Peng Yang†, Xiao Zhou‡*, Xuefeng Yang¹, Yuefeng Wang¹, Tao Sun¹, Shiyeng Feng¹ and Xianyou Ma¹

Abstract

Background: Camrelizumab (a PD-1 inhibitor) has been used as a potential therapy in unresectable advanced esophageal squamous cell carcinoma (ESCC) along with adjuvant treatment in locally advanced ESCC, exhibiting an acceptable efficacy and safety profile. This pilot study was designed to further investigate the clinical value and tolerance of neoadjuvant camrelizumab plus chemotherapy in locally advanced ESCC.

Methods: A total of 16 patients with locally advanced ESCC were recruited. Patients received 2 cycles of neoadjuvant therapy including 2 doses of camrelizumab concurrent with 2 cycles of paclitaxel plus carboplatin followed by surgery 4 weeks afterward. Then, the treatment response after neoadjuvant therapy, R0 resection rate, tumor regression grade (TRG), and pathological complete remission (pCR) rate were measured. Besides, adverse events were documented. At last, progression-free survival (PFS) and overall survival (OS) were assessed.

Results: Generally, objective remission rate (ORR) was 81.3% whereas disease control rate (DCR) was 100% after neoadjuvant therapy. Concerning TRG grade, 31.3, 37.5, 18.8, and 12.5% patients reached TRG0, TRG1, TRG2, and TRG3, respectively. Then, pCR rate and R0 resection rate were 31.3 and 93.8%, respectively. Besides, mean PFS and OS were 18.3 months (95%CI: (16.2–20.5) months) and 19.2 months (95%CI: (17.7–20.7) months), respectively, with a 1-year PFS of 83% and OS of 90.9%. Adverse events included white blood cell decrease (37.5%), neutrophil decrease (31.3%), reactive cutaneous capillary endothelial proliferation (37.5%), and nausea or vomiting (25.0%), which were relatively mild and manageable.

Conclusion: Neoadjuvant camrelizumab plus chemotherapy exhibits good efficacy and acceptable tolerance in patients with locally advanced ESCC.

Keywords: Camrelizumab, Chemotherapy, Neoadjuvant therapy, Esophageal squamous cell carcinoma, Efficacy and safety

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Esophageal squamous cell carcinoma (ESCC), with a proportion of 87% in all esophageal cancer, exhibits a more extensive intratumor heterogeneity and a higher mortality [1–3]. Surgery is the most common treatment modality for the ESCC patients; however, as to patients with locally advanced ESCC, they always lose surgical...
opportunities because of the large tumor size. Fortunately, the emergence of neoadjuvant therapy not only decreases the tumor size but also brings more surgical opportunities to the patients with locally advanced ESCC [4, 5].

Chemotherapy is the first prior neoadjuvant therapy recommended by several guidelines [6–8] for these patients. Recently, several researches indicate that some certain targeted drugs (such as apatinib and nivolumab) in combination with chemotherapy probably promote the survival profile in locally advanced ESCC [9–11].

Programmed cell death protein 1 (PD-1), expressed by activated lymphocytes, blocks immune responses and facilitates immune escape by binding to its ligands including programmed cell death ligand 1 (PD-L1), which further contributes to tumorigenesis and disease progression in various malignancies [12, 13]. PD-1 inhibitor, as a novel developed immune therapy, blocks the PD-1/PD-L1 linkage and has been widely applied in numerous carcinomas [12, 14]. In addition, in locally advanced ESCC, nivolumab and pembrolizumab combination with chemotherapy was recently used for neoadjuvant therapy, which exhibited an acceptable therapeutic response, progression-free survival (PFS), and overall survival (OS) [9]. Camrelizumab, a domestic product developed in China, is a novel IgG4-kappa anti-PD-1 inhibitor that has been used for treatment of a variety of malignancies, such as refractory classical Hodgkin's lymphoma and gastric or gastroesophageal junction adenocarcinoma [15, 16]. Moreover, camrelizumab has been previously witnessed for adjuvant or second-line therapy of locally advanced ESCC [17, 18]. However, the clinical value of neoadjuvant camrelizumab plus chemotherapy in the treatment for locally advanced ESCC has not been reported before.

Thus, this study aimed to explore the therapeutic response, survival, and safety profiles of neoadjuvant camrelizumab plus chemotherapy in treating locally advanced ESCC.

Methods

Patients
The current study was a prospective study. A total of 16 patients with locally advanced ESCC who were recruited between July 1, 2019, and December 31, 2020, and received camrelizumab combined with chemotherapy as neoadjuvant therapy before surgery in our hospital. The inclusion criteria were as follows: (i) histologically confirmed as ESCC; (ii) potentially curable and locally advanced ESCC, which was defined as cT1N1-3M0 or cT2-4aN0-3M0 (Union for International Cancer Control, UICC Version 8.0) [19]; (iii) aged >18 years old; (iv) Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1; (v) willing to receive the neoadjuvant therapy of camrelizumab combined with paclitaxel and carboplatin; and (vi) able to be regularly follow-up. The exclusion criteria were as follows: (i) poorly controlled underlying diseases or insufficient hepatic, hematological, and kidney functions that led to be unsuitable for neoadjuvant therapy; (ii) hypersensitivity to the study drugs; (iii) difficult to perform gastric tube reconstruction after esophagectomy; (iv) known concurrent malignancies; (v) severe infections; (vi) history of use of camrelizumab, paclitaxel or carboplatin; and (vii) pregnancy. Ethical permission for this study was obtained from the Institutional Review Board with the approval number of KS1951 on 11th May 2019, and the written informed consents were acquired from all patients. Our study was registered on Chinese Clinical Trial Registry (https://www.chictr.org.cn/index.aspx) with the approval number of “ChiCTR2100051903”.

Neoadjuvant therapy and surgery
All patients received 2 cycles of neoadjuvant therapy, including 2 doses of camrelizumab concurrent with 2 cycles of paclitaxel plus carboplatin. In detail, the camrelizumab was administered intravenously at a dose of 200 mg each time, every 3 weeks (a treatment cycle). Simultaneously, the paclitaxel was administered by intravenous drip at a dose of 100 mg/m² of body-surface area on days 1 and 8, and the carboplatin was administered by intravenous drip and targeted at an area under the curve of 5 mg/ml per minute on day 1. The surgery was performed approximately 4 weeks after completion of 2 cycles of neoadjuvant therapy, and the type of surgery included minimally invasive esophagectomy, right transthoracic open esophagectomy, or hybrid approaches (using video-assisted thoracoscopy and laparotomy) with a total 2-field lymphadenectomy. Complete thoracoabdominal two-field lymph node dissection (standard thoracoabdominal two-field plus mediastinum, especially bilateral recurrent laryngeal nerve chain lymph nodes) was performed for the patients without suspicious enlarged lymph nodes in the neck and the patients with middle and lower thoracic esophageal cancer. Cervical-thoracoabdominal three-field lymph node dissection (upper and lower neck and supraclavicular complete two-field lymph nodes mentioned above) was performed for the patients with suspiciously swollen lymph nodes in the neck and patients with upper thoracic esophageal cancer. As for adjuvant therapy, patients received paclitaxel plus carboplatin regimen for about 2–4 cycles.

Treatment response evaluation and safety assessment
The primary endpoint was pathological complete remission (pCR), and the secondary endpoints included treatment response, tumor regression grade (TRG), R0
resection rate, adverse events, progression-free survival (PFS), and overall survival (OS). After the completion of 2 cycles of neoadjuvant therapy, a preoperative computed tomography (CT) examination was performed to assess the treatment response according to the Response Evaluation Criteria In Solid Tumors (RECIST Version 1.1) [20]. Meanwhile, objective remission rate (ORR) and disease control rate (DCR) were calculated as follows: ORR = complete remission (CR) rate plus partial remission (PR) rate and DCR = CR rate plus PR rate plus stable disease (SD) rate. After surgery, pathological examination of the resection specimens was conducted to evaluate the resection margin status and tumor regression grade (TRG). R0 resection was defined as no cancer cells at resection margins. The TRG was used for assessment of the degree of histomorphological degeneration, which was classified as follows: grade 0, no residual cancer cells (defined as pCR); grade 1, single cell or small groups of cancer cells; grade 2, residual cancer cells outgrown by fibrosis; and grade 3, minimum or no treatment effect and extensive residual cancer cells [21, 22]. In addition, adverse events occurred during the neoadjuvant therapy were documented in detail to access safety profiles, which consisted mainly of hematologic adverse events and non-hematologic adverse events.

Survival assessment
For assessment of progression-free survival (PFS) and overall survival (OS), the postoperative surveillance and follow-up for patients were implemented every 3 months in the first year then every 6 months in the following years.

Statistical analysis
Data processing and graph plotting were carried out with the use of SPSS 26.0 (IBM Corp., Armonk, NY, USA) and GraphPad Prism 6.02 (GraphPad Software Inc., San Diego, CA, USA). Descriptive analysis was completed with the use of the statistics including mean with standard deviation (SD), median with interquartile range (IQR), and frequency with percentage. Survival curves were plotted using Kaplan-Meier method.

Results
Baseline characteristics
In total, 16 patients with locally advanced ESCC were enrolled in present study (Table 1). The age was 60.9±7.8 years. Regarding gender, the number of male and female patients was 14 (87.5%) and 2 (12.5%), respectively. Moreover, 13 (81.3%) patients were scored as ECOG PS score 0, while 3 (18.8%) patients were scored as ECOG PS score 1. Besides, the distribution of tumor location was listed as follows: 3 (18.8%) patients with proximal third, 8 (50.0%) patients with middle third, and 5 (31.3%) patients with distal third. Furthermore, there were 0 (0.0%), 4 (25.0%), 10 (62.5%), and 2 (12.5%) patients were diagnosed as TNM stage I, stage II, stage III, and stage IV, respectively. The detailed characteristics were shown in Table 1.

Table 1 Characteristics of locally advanced ESCC patients

| Characteristics               | ESCC patients (N = 16) |
|-------------------------------|------------------------|
| Age (years)                   | Median (IQR) 60.5 (56.0-67.3) |
|                               | Mean±SD 60.9±7.8       |
| Male, No. (%)                 | 14 (87.5)              |
| ECOG PS, no. (%)              |                        |
| 0                             | 13 (81.3)              |
| 1                             | 3 (18.8)               |
| Tumor location, no. (%)       |                        |
| Proximal third                | 3 (18.8)               |
| Middle third                  | 8 (50.0)               |
| Distal third                  | 5 (31.3)               |
| Histological grade, no. (%)   |                        |
| Well                          | 1 (6.3)                |
| Moderate                      | 8 (50.0)               |
| Poor                          | 7 (43.7)               |
| Clinical T stage, no. (%)     |                        |
| cT1                           | 0 (0.0)                |
| cT2                           | 2 (12.5)               |
| cT3                           | 13 (81.3)              |
| cT4                           | 1 (6.3)                |
| Clinical N stage, no. (%)     |                        |
| N0                            | 2 (12.5)               |
| N1                            | 10 (62.5)              |
| N2                            | 3 (18.8)               |
| N3                            | 1 (6.3)                |
| Clinical TNM stage, no. (%)   |                        |
| Stage I                       | 0 (0.0)                |
| Stage II                      | 4 (25.0)               |
| Stage III                     | 10 (62.5)              |
| Stage IV                      | 2 (12.5)               |

ESCC esophageal squamous cell carcinoma, IQR interquartile range, SD standard deviation, ECOG PS Eastern Cooperative Oncology Group performance status

Treatment response
After neoadjuvant therapy, 4 (25.0%) patients achieved CR, 9 (56.3%) patients reached PR and 3 (18.8%) patients remained SD, whereas no one got progressive disease (PD) (Fig. 1a). To sum up, ORR was 81.3%; meanwhile, DCR was 100% (Fig. 1b). Regarding tumor regression grade, 5 (31.3%), 6 (37.5%), 3 (18.8%), and 2 (12.5%) patients reached TRG 0, TRG 1, TRG 2, and TRG 3, respectively (Fig. 2a). Furthermore, 5 (31.3%) patients...
achieved pCR (Fig. 2b). Besides, 15 (93.8%) patients realized R0 resection.

Survival profiles
The mean PFS was 18.3 months (95%CI: (16.2–20.5) months) with a 1-year PFS rate of 83% (Fig. 3a); meanwhile, the mean OS was 19.2 months (95%CI: (17.7–20.7) months) with a 1-year OS rate of 90.9% (Fig. 3b). In addition, the detailed information of each patient in terms to baseline characteristics, responses, and survival data was listed in Table 2.
Table 2: Key features and treatment outcomes of each advanced ESCC patient

| No. | Age (years) | Gender | ECOG PS | Location            | Clinical T stage | Clinical N stage | Clinical TNM stage | Treatment response | TRG | pCR | R0 resection | Progression | PFS (months) | Death | OS (months) |
|-----|-------------|--------|---------|---------------------|------------------|------------------|--------------------|--------------------|-----|-----|--------------|-------------|--------------|-------|-------------|
| 1   | 57          | M      | 0       | Proximal third      | T3               | N0               | Stage II           | CR                 | 1   | No | Yes          | No          | 16           | No    | 16          |
| 2   | 64          | M      | 0       | Proximal third      | T2               | N1               | Stage II           | CR                 | 0   | Yes| Yes         | No          | 13           | No    | 13          |
| 3   | 61          | M      | 0       | Middle third        | T3               | N1               | Stage III          | PR                 | 0   | Yes| Yes         | No          | 20           | No    | 20          |
| 4   | 65          | M      | 0       | Proximal third      | T3               | N2               | Stage III          | PR                 | 2   | No | Yes          | No          | 18           | No    | 18          |
| 5   | 52          | M      | 0       | Distal third        | T2               | N1               | Stage II           | SD                 | 1   | No | Yes          | No          | 16           | No    | 16          |
| 6   | 68          | M      | 0       | Middle third        | T3               | N1               | Stage III          | PR                 | 0   | Yes| Yes         | No          | 7            | No    | 7           |
| 7   | 70          | M      | 0       | Distal third        | T3               | N0               | Stage II           | PR                 | 0   | Yes| Yes         | No          | 10           | No    | 10          |
| 8   | 58          | M      | 0       | Middle third        | T3               | N1               | Stage III          | PR                 | 1   | No | Yes          | No          | 17           | No    | 17          |
| 9   | 53          | M      | 1       | Distal third        | T3               | N2               | Stage III          | PR                 | 1   | No | Yes          | Yes         | 13           | No    | 16          |
| 10  | 72          | F      | 1       | Middle third        | T3               | N3               | Stage IV           | SD                 | 3   | No | No          | Yes         | 6            | Yes   | 11          |
| 11  | 56          | M      | 1       | Middle third        | T3               | N1               | Stage III          | CR                 | 1   | No | Yes          | No          | 9            | No    | 9           |
| 12  | 46          | M      | 0       | Distal third        | T3               | N1               | Stage III          | PR                 | 2   | No | Yes          | No          | 6            | No    | 6           |
| 13  | 62          | M      | 0       | Distal third        | T3               | N2               | Stage III          | PR                 | 1   | No | Yes          | No          | 12           | No    | 12          |
| 14  | 60          | F      | 0       | Distal third        | T3               | N1               | Stage III          | CR                 | 0   | Yes| Yes         | No          | 15           | No    | 15          |
| 15  | 56          | M      | 0       | Middle third        | T4               | N1               | Stage IV           | PR                 | 3   | No | Yes          | No          | 4            | No    | 4           |
| 16  | 75          | M      | 0       | Middle third        | T3               | N1               | Stage III          | SD                 | 2   | No | Yes          | No          | 16           | No    | 16          |

ESCC: esophageal squamous cell carcinoma, ECOG PS: Eastern Cooperative Oncology Group performance status, TRG: tumor regression grade, pCR: pathologic complete remission, PFS: progression-free survival, OS: overall survival, M: male, F: female, CR: complete remission, PR: partial remission, SD: stable disease, PD: progressive disease.
Adverse events

Regarding hematological adverse events, 6 (37.5%), 5 (31.3%), 2 (12.5%), and 2 (12.5%) patients experienced white blood cell (WBC) reduction, neutrophil decreased, thrombocytopenia, and anemia (Table 3). Regarding non-hematologic adverse events, 6 (37.5%), 4 (25.0%), 3 (18.8%), 2 (12.5%), 2 (12.5%), 1 (6.3%), and 1 (6.3%) patients suffered from reactive cutaneous capillary endothelial proliferation (RCCEP), nausea or vomiting, decreased appetite, baldness, diarrhea, constipation, fatigue, and rash.

Discussion

In present study, it was revealed that (1) after the neoadjuvant therapy, ORR was 81.3% and DCR was 100%. (2) In surgery, the pCR rate and R0 resection rate were 31.3 and 93.8%, respectively. (3) The 1-year PFS and OS were 83 and 90.9%, respectively. (4) All adverse events were slight and tolerable.

Currently, the chemotherapy and radiotherapy are recommended neoadjuvant therapy for locally advanced ESCC patients [6–8]. What’s more, some recent studies point out that targeted drugs (such as apatinib, pembrolizumab, and nivolumab) combined with chemotherapy could possibly exhibit an even better efficacy for the locally advanced ESCC patients. However, there is little evidence around neoadjuvant camrelizumab combined with chemotherapy in treating locally advanced ESCC patients. Subsequently, the current study turn attention to camrelizumab, a PD-1 immune checkpoint inhibitor, which blocks the binding site of PD-1 expressed on activated T lymphocytes, B cells, and natural killer cells to PD-L1 overexpressed on certain cancer cells. So far, several studies report that camrelizumab combined with chemotherapy has been used in adjuvant and second-line therapy of locally advanced ESCC and exhibits a promising antitumor efficacy [17, 18]. However, the clinical value of neoadjuvant camrelizumab combined with chemotherapy in locally advanced ESCC is still unclear. In present study, patients receiving neoadjuvant camrelizumab combined with chemotherapy reached an ORR of 81.3% and DCR of 100% in locally advanced ESCC patients. Possible explanations might be that (1) camrelizumab blocked the binding of PD-1 to PD-L1; promoted the activation of monocytes, T cells, B cells, dendritic cells, and tumor-infiltrating lymphocytes to exert tumor suppressive function; and furthermore contributed to better therapeutic response [23]. (2) Besides, chemotherapy might help to activate tumor-specific T cells by promoting tumor antigen presentation and by destroying immunosuppressive factors and further promotes the antitumor efficacy of camrelizumab [24]. Hence, synergic effect of cytotoxic chemotherapy plus camrelizumab probably results in a favorable therapeutic response.

Regarding pathological response, previous studies exhibited that an R0 resection rate was 96.3% and a pCR rate was 33.3% in patients with locally advanced ESCC receiving neoadjuvant nivolumab and pembrolizumab plus chemotherapy [9]. Likewise, in another study, pCR rate was 34.21%; meanwhile, R0 resection rate was 92.11% in locally advanced ESCC patients receiving neoadjuvant camrelizumab and pembrolizumab plus chemotherapy [25]. In this present study, 5 (31.3%), 6 (37.5%), 3 (18.8%), and 2 (12.5%) patients reached TRG 0, TRG 1, TRG 2, and TRG 3, respectively; 31.3% patients had pCR; meanwhile, 93.8% patients were witnessed with R0 resection. Possible explanations were as follows: (1) Camrelizumab may promote the cytotoxic effect of chemotherapy in tumor cells through elevating the chemosensitivity in patients with locally advanced ESCC; therefore, camrelizumab plus chemotherapy might present a better tumor suppressive effect than neoadjuvant chemotherapy alone, contribute to improve R0 resection rate, pCR rate, and tumor regression effect [26]. (2) Camrelizumab suppresses tumor angiogenesis and stimulates antineoplastic activities, which could be facilitated by chemotherapy [27]. Hence, the neoadjuvant camrelizumab plus chemotherapy might elevate the antitumor efficiency and further achieve a favorable R0 resection rate, pCR rate, and tumor regression effect in patients with locally advanced ESCC.

So far, few studies investigate the survival profile of neoadjuvant PD-1 inhibitors plus chemotherapy in patients with locally advanced ESCC. In the present

Table 3 Adverse events during neoadjuvant therapy

| Adverse events                  | ESCC patients (N = 16) |
|--------------------------------|------------------------|
| **Hematologic, no. (%)**       |                        |
| WBC decreased                  | 6 (37.5)               |
| Neutrophil decreased           | 5 (31.3)               |
| Anemia                         | 2 (12.5)               |
| Thrombocytopenia               | 2 (12.5)               |
| **Non-hematologic, no. (%)**   |                        |
| RCCEP                          | 6 (37.5)               |
| Nausea or vomiting             | 4 (25.0)               |
| Decreased appetite             | 3 (18.8)               |
| Baldness                       | 3 (18.8)               |
| Diarrhea                       | 2 (12.5)               |
| Constipation                   | 2 (12.5)               |
| Fatigue                        | 1 (6.3)                |
| Rash                           | 1 (6.3)                |

ESCC esophageal squamous cell carcinoma, WBC white blood cell, RCCEP reactive cutaneous capillary endothelial proliferation
study, it was revealed that with neoadjuvant camrelizumab plus chemotherapy treatment, the mean PFS and OS were 18.3 months and 19.2 months with a 1-year PFS of 83% and 1-year OS of 90.9%, respectively. These findings might be explained by the following hypotheses: (1) Camrelizumab may promote the cytotoxic effect of chemotherapy on tumor cells through increasing the chemosensitivity. Furthermore, camrelizumab combined with chemotherapy might present a better tumor suppressing efficacy particularly in less immunogenic, chemo-sensitive tumors [26]. (2) Neoadjuvant camrelizumab combined with chemotherapy achieves a good treatment response and satisfactory pCR rate, as discussed above, which may contribute to improve prognosis in present research.

Concerning camrelizumab for the treatment of gastric cancer and esophagus cancer, the major adverse events were discovered in the skin, gastrointestinal tract, endocrine glands, liver, and lung; meanwhile, most of them were mild and manageable [28]. As to the current study, the major adverse events include white blood cell (WBC) reduction, neutrophil decreased, RCCPE, nausea, or vomiting, most of which were mild and controllable. It is indicated that neoadjuvant camrelizumab combined with chemotherapy was well-tolerant as the neoadjuvant therapy of locally advanced ESCC.

Limitations were as followed: (1) The relatively small sample size of eligible patients might potentially reduce the reliability of the results. (2) As this was a single-arm study, it lacks a control group; hence, further randomized, controlled study would be desirable. (3) Follow-up period was relatively short, and further study with a longer follow-up period was necessary to determine the long-term efficacy of neoadjuvant camrelizumab combined with chemotherapy in patients with locally advanced ESCC. (4) The economic evaluation of camrelizumab combined with chemotherapy was neglected in the current study, which needs further exploration. (5) In the present study, patients’ selection bias might exist to affect the survival profile.

Conclusions
Collectively, neoadjuvant camrelizumab plus chemotherapy exhibits good efficacy and acceptable tolerance in treating patients with locally advanced ESCC, while further validation of the efficacy in larger cohort is needed.

Abbreviations
ESCC: Esophageal squamous cell carcinoma; TRG: Tumor regression grade; pCR: Pathological complete remission; PFS: Progression-free survival; OS: Overall survival; ORR: Objective remission rate; DCR: Disease control rate; PD-1: Programmed cell death protein 1; PD-L1: Programmed cell death ligand 1; CT: Computed tomography; CR: Complete remission; PR: Partial remission; SD: Stable disease; IQR: Interquartile range.
8. Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, et al. Esophageal and esophagogastric junction cancers, version 2.2019. NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(7):855–83.
9. Shen D, Chen Q, Wu J, Li J, Tao K, Jiang Y. The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma. J Gastrointest Oncol. 2021;12(1):1–10.
10. Fukuoka E, Yamashita K, Tanaka T, Sawada R, Sugita Y, Arimoto A, et al. Neoadjuvant chemotherapy increases PD-L1 expression and CDB(+) tumor-infiltrating lymphocytes in esophageal squamous cell carcinoma. Anticancer Res. 2019;39(8):4539–48.
11. Hu L, Kong Z, Meng Q, Wang J, Zhou M, Yu J, et al. The safety and efficacy of apatinib treatment in addition to concurrent chemoradiotherapy in patients with nonoperative locally advanced esophageal squamous cell carcinoma. Med Sci Monit. 2020;26:e927221.
12. Yamamoto S, Kato K, Daiko H, Kojima T, Hara H, Abe T, et al. Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTIER (UCDG1804E). Future Oncol. 2020;16(19):1351–7.
13. Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Commun. 2020;40(12):711–20.
14. Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255–68.
15. Zheng Y, Wang Z, Yan C, Yan M, Hou Z, Zheng R, et al. Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma. Ann Transl Med. 2020;8(24):1684.
16. Liu Y, Wang C, Li X, Dong L, Yang Q, Chen M, et al. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus dectinab in relapsed/refractory Hodgkin lymphoma. J Immunother Cancer. 2021;9(4):e002347.
17. Zhang B, Qi L, Wang X, Xu J, Liu Y, Mu L, et al. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma. Cancer Commun. 2020;40(12):711–20.
18. Zhang W, Yan C, Gao X, Li X, Cao F, Zhao G, et al. Safety and feasibility of radiotherapy plus camrelizumab for locally advanced esophageal squamous cell carcinoma. Oncologist. 2021;26(7):e1110–e24.
19. Fang W. Interpretation of 2017 National Comprehensive Cancer Network (NCCN) guidelines for the diagnosis and treatment of esophageal squamous cell carcinoma through the new TNM staging of esophageal carcinoma (eighth edition) by the Union for International Cancer Control (UICC) and the American Cancer Commission (AJCC). Zhonghua Wei Chang Wai Ke Za Zhi. 2017;20(10):1122–6.
20. Schwartz LH, Litierre S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. REGIST 1.1-Update and clarification: from the REGIST committee. Eur J Cancer. 2016;62:132–7.
21. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinopathologic correlations. Cancer. 1994;73(11):2680–6.
22. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemomoradiation. Cancer. 2005;103(7):1347–55.
23. Alsaab HQ, Sau S, Alzharni R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 Checkpoint signaling inhibition for cancer immunotherapy: mechanisms, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.
24. Chen G, Emens LA. Checkmioimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother. 2013;62(2):203–16.
25. Wu Z, Zheng Q, Chen H, Xiang J, Hu H, Li H, et al. Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma. J Thorac Dis. 2021;13(6):3518–28.
26. Chowdhury PS, Chamoto K, Honjo T. Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. J Intern Med. 2018;283(2):110–20.
27. Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014;21(1):15–25.
28. Wang D, Zhang S, Ding P, Zhao Y, Zhang X, Zhao Q. Immune-related adverse events mimicking Behcet’s disease in a gastric cancer patient following camrelizumab treatment. Iran J Immunol. 2020;17(2):167–71.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.